Federal Rules on 7-OH and Synthetic Kratom Tighten: What the New Threshold Means

On October 9, 2026, the U.S. Department of Justice announced updated emergency scheduling actions covering 7-hydroxymitragynine (7-OH) and three related compounds: mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16. The change rests on a new scientific analysis from the Department of Health and Human Services, which recommended a specific concentration threshold to separate kratom products that have been enhanced or concentrated from products whose chemistry still looks like the plant.

For families who have spent the past year reading warnings about 7-OH gummies, "enhanced" kratom shots and products sold as concentrates in smoke shops, gas stations and convenience stores, this is the clearest federal line drawn so far. It is also easy to misread — and a misread matters, because the difference between the two sides of that line is the difference between a botanical supplement and an opioid-receptor drug.

Here is what actually changed, and what it means in practice.

What the government announced

In its statement, the Justice Department said the Drug Enforcement Administration is issuing two new Notices of Intent based on updated HHS science. Attorney General Todd Blanche framed the action plainly: "Dangerous and addictive opioids do not belong behind convenience store counters. Our nation's children and communities deserve protection from harmful substances like 7-OH and other powerful synthetic drugs."

A Notice of Intent is a procedural step, not the final rule. It opens a 30-day period during which the agency signals what it intends to do before issuing a new temporary scheduling order.

The threshold, in plain language

HHS recommended that 7-OH and MGPI fall under Schedule I control when any of the following is true:

either substance alone — or the two combined — exceeds 1 milligram per gram in solid products;
it exceeds 1 milligram per milliliter in liquid products; or
the ratio of mitragynine to 7-OH, MGPI, or the two combined is less than 100 to 1.

Translated: a kratom product whose alkaloid profile looks like the leaf stays where it is. A product that has been deliberately spiked, concentrated or manufactured to deliver a large dose of 7-OH or MGPI crosses the line and is treated as a controlled substance.

HHS said its analysis "confirms that 7-OH occurs naturally in botanical kratom at relatively low levels" and notes that MGPI may also appear at trace levels in some botanical or kratom-derived products. That is exactly why a threshold was recommended instead of a blanket ban on anything containing the compound — and why the agency says the science on MGPI is still developing.

What did not change — and what is still unresolved

Two nuances are easy to lose in the headlines:

MGPI, MGM-15 and MGM-16 are already Schedule I. DEA placed them there temporarily on August 26, 2026, on an official finding that they pose "an imminent hazard to public safety." Those controls remain in effect through the new 30-day Notice of Intent period and until DEA issues a replacement order.
7-OH itself is not scheduled yet. DEA had not issued a temporary scheduling order for 7-OH. It will now reissue a fresh Notice of Intent reflecting HHS's updated recommendation — which follows the July 6, 2026 request for information and the comment period that was extended in August.

So the honest summary is this: the engineered, concentrated versions of kratom are being pushed out of the legal market. Botanical kratom below the threshold is not what this action targets.

Why concentration is the safety issue

The clinical reason a concentration threshold exists comes down to one mechanism.

Kratom — Mitragyna speciosa — contains many alkaloids, but two are best studied: mitragynine and 7-hydroxymitragynine (7-OH). Both partially activate mu-opioid receptors, the same molecular target as heroin, oxycodone and fentanyl. According to NIDA, neither kratom leaves nor mitragynine generally produce the respiratory depression that makes an opioid overdose life-threatening — but in laboratory models, 7-OH can cause respiratory depression that is reversed by naloxone.

That single sentence explains the entire regulatory exercise. The gap between botanical kratom and an "enhanced" product is not a marketing distinction; it is the difference between a substance that has not been shown to stop breathing in lab models and one that has. NIDA also cautions that kratom product effects are hard to predict — potency, formulation, contaminants and other substances in someone's system all change the picture — and that the FDA has approved kratom for no medical use.

Recent events show what that unpredictability looks like in practice. On October 5, 2026, Utah's health department, poison control center and agriculture department issued a joint warning after four deaths were linked to products sold as "cat's claw" — a benign botanical — that actually contained MGPI and MGM-15. Utah's agriculture department described synthetic kratom concentrates as "significantly more potent than morphine at opioid receptors." Officials there said naloxone is effective against overdoses from these compounds, and that standard, evidence-based opioid withdrawal treatment applies.

The lesson from Utah is the one this federal action is built around: what matters is not what the package calls the product, but how concentrated the opioid-receptor compounds inside it are.

What to do if you or someone you know buys these products

This is information, not a judgment. A few practical points:

A negative fentanyl test strip says nothing about 7-OH or MGPI. Standard strips are built to detect fentanyl. They will not tell you about kratom compounds, so a negative result is not a green light.
Treat label claims as unreliable. Utah's warning added a useful rule of thumb: a product that claims to be legal and warns it is for adults 21 and over or promises a strong psychoactive high is telling you two contradictory things. That contradiction is a warning sign.
Do not judge a dose by the label. Products differ, batches differ, and effects are unpredictable. Taking less is the only reliable lever a user has.
Do not use alone. If someone is going to use anyway, having another person present — or using a service like the National Overdose Prevention Line for people who use alone — changes the odds of surviving an overdose.
Keep naloxone within reach, not in a drawer. More than one dose is better than one. It is available without a prescription in most states, is often free through local health departments and syringe services programs, and can be mailed in many areas.
Talk to a clinician before stopping abruptly. If someone has been using concentrated kratom products daily, the days right after stopping carry their own risk. Medical support is safer than a solo taper, and medications for opioid use disorder — buprenorphine and methadone — are approved, effective and far safer than any unregulated retail product.

If someone overdoses

Because 7-OH and MGPI act on opioid receptors, naloxone works — but naloxone is temporary. NIDA notes that it reverses an opioid overdose in the body for only 30 to 90 minutes, while the drug itself remains in the body longer. The overdose can return, and stronger compounds may require multiple doses. That is why the most important step is calling 911.

Signs to act on: unresponsiveness or difficulty waking someone, slow or shallow breathing, choking, gurgling or snoring sounds, blue or gray lips and fingertips, and pinpoint pupils. Give naloxone right away, call 911, lay the person on their side, and stay with them. Most states have Good Samaritan laws that protect people who call for help. Our first 72 hours after an overdose guide walks through what happens next.

Where to get help

SAMHSA National Helpline: 1-800-662-4357 — free, confidential, 24/7, English and Spanish.
Find a treatment provider: findtreatment.gov
988 Suicide & Crisis Lifeline: call or text 988.
Poison Control: 1-800-222-1222 — 24/7, free, confidential.
Emergency: 911.

What happens next

The 30-day Notice of Intent period gives DEA the runway to issue — or reissue — temporary scheduling orders for 7-OH and the related compounds, with MGPI, MGM-15 and MGM-16 already controlled in the meantime. In practice, that means the concentrated products this rule describes are heading off the legal market, and the department has signalled that it intends to pursue the traffickers distributing them.

For families, the useful takeaway does not depend on any of that. The concentrated products were already the ones linked to deaths and to the warnings in Utah; a threshold published in Washington does not change what is sitting on a shelf today. If there is a product in your home that promises a strong opioid-like high, or a package labelled "cat's claw" that also warns it is for adults only, that is the one to talk about — calmly, and with a plan for what happens next.